Meetings

Explore how a comprehensive, integrative systems approach—using omics technologies, big data, and AI—could transform cardiovascular disease treatment worldwide.

AI and the Future of Cancer Research and Cancer Care to Headline October 24 Gathering of Global Oncology Leaders at the National Press Club: NFCR Global Summit to Feature Top Scientists, Entrepreneurs, and Cancer-Care Innovators

Event spotlights “what’s next” in cancer breakthroughs, entrepreneurship, and patient care, culminating in honoring Dr. Tony Hunter with the 2025 Szent-Györgyi Prize for Progress in Cancer Research

Hundreds of physicists from around the world will convene to present new research at the 67th annual meeting of the American Physical Society’s Division of Plasma Physics. The conference will be held online and in person at the Long Beach Convention Center in Long Beach, California Nov. 17-21.

Speaking at the European Parliament’s Panel for the Science and Technology Options Assessment (STOA) workshop “Data Sovereignty in Research: Global Dependencies, Risks, and the European Response”, Mehmet Toral, Chief Corporate Officer and General Counsel of Frontiers, encouraged Europe to look beyond guaranteeing data resilience and access, and continue to position itself as the global leader in science.

Explore the potential for hybrid alternative protein-based foods as healthier, tastier, more sustainable alternatives to animal products.

Previously, the primary endpoint results of the NRG-LU005 study assessing the addition of the immunotherapy drug atezolizumab to standard of care concurrent chemoradiation for limited-state small cell lung cancer was reported at the American Society for Radiation Oncology 2024 Annual Meeting. Those results showed that adding atezolizumab did not improve overall survival (OS) for this patient population. At the same time, an exploratory analysis reported longer median OS among patients who received twice-a-day radiation, though RT schedule was not randomized. As a follow up to that study, a patient-reported outcomes (PRO) analysis explored the impact of the NRG-LU005 treatment regimens on quality of life (QOL). The results of this PRO analysis were recently reported as a late-breaking abstract at the ASTRO 2025 Annual Meeting in San Francisco, California.

Previously, results from the photon cohort of the NRG-BN001, a signal seeking Phase II randomized trial, indicated that photon radiation dose intensification (75 Gy) did not demonstrate improvement in overall survival (OS) for patients with newly diagnosed glioblastoma (GBM). The recent analysis of the proton cohort revealed improved survival for patients receiving proton therapy at 75 Gy. Because this data met the pre-defined survival improvement threshold, they could be used to design and conduct a definitive phase III randomized trial.

Results from the health-related quality of life (HRQOL) analysis of the University of Pennsylvania and RTOG Foundation RadComp study indicated that both photon and proton radiation treatment options yielded similar, excellent HRQOL outcomes for women with non-metastatic breast cancer. RadComp was the first randomized study comparing proton to photon radiation for breast cancer treatment.

Results of the NRG Oncology NRG-GU005 clinical study comparing stereotactic body radiation therapy (SBRT) to moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) for patients with localized immediate risk prostate cancer indicate that the use of SBRT improved bowel health related quality of life (HRQOL) in this patient population. There was no significant improvement seen for the other primary objectives including urinary HRQOL and there was a lack of improvement in distant-free survival for patients.